ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Interest Expense : HK$-1.67 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ImmuneOnco Biopharmaceuticals (Shanghai)'s interest expense for the six months ended in Dec. 2023 was HK$ -0.98 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.67 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ImmuneOnco Biopharmaceuticals (Shanghai)'s Operating Income for the six months ended in Dec. 2023 was HK$ -214.88 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Interest Expense for the six months ended in Dec. 2023 was HK$ -0.98 Mil. ImmuneOnco Biopharmaceuticals (Shanghai) did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ImmuneOnco Biopharmaceuticals (Shanghai) Interest Expense Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Interest Expense Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Interest Expense

-1.09

-0.88

-1.67

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	-	-0.49	-0.41	-0.69	-0.98

ImmuneOnco Biopharmaceuticals (Shanghai) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.67 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Interest Expense for the six months ended in Dec. 2023 was HK$-0.98 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-214.88 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$11.37 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

ImmuneOnco Biopharmaceuticals (Shanghai) did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines